Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
April 24, 2013 Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting ...
February 19, 2013 Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease ...
December 19, 2012 Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically Delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease ...
May 8, 2012 Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing ...
April 24, 2012 Eleven Biotherapeutics to Present at the ARVO 2012 Annual Meeting ...
September 22, 2011 Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer ...
January 6, 2011 Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development ...
November 5, 2010 Eleven Biotherapeutics Receives Three Federal Grants to Develop Innovative Protein-Based Therapeutics ...
September 15, 2010 Eleven Biotherapeutics Named One of the "Fierce 15" Leading Biotech Companies of 2010 ...
February 17, 2010 Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics ...
FirstPrevious ...
10
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
1.58
Change:
- 0.03
Day High:
1.67
Day Low:
1.54
Volume:
246,761
12:12 PM ET on September 20, 2017
Delayed at least 20 minutes.